Aarti Drugs Limited (AARTIDRUGS) Financial History

Name: Aarti Drugs Limited (AARTIDRUGS) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-09-20

Aarti Drugs Limited (AARTIDRUGS) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Mumbai, India with about 1,355 employees. Its market capitalization is roughly ₹39 billion. In the fiscal year ended 2026-03-31, AARTIDRUGS reported ₹25.2B in revenue and ₹1.9B in net income.

Aarti Drugs Limited, through its subsidiaries, engages in the manufacture and marketing of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally.

Interactive charts & full statements →

AARTIDRUGS Revenue & Earnings History — Annual Income Statement

Income statement	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Total Revenue	₹25.2B	₹23.7B	₹25.1B	₹27.1B
Gross Profit	₹5.1B	₹4.8B	₹4.8B	₹4.8B
Operating Income (EBIT)	₹2.5B	₹2.4B	₹2.8B	₹2.7B
Net Income	₹1.9B	₹1.7B	₹1.7B	₹1.7B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AARTIDRUGS Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Total Revenue	₹7.0B	₹7.2B	₹6.0B	₹6.5B	₹5.9B
Gross Profit	₹2.8B	₹2.7B	₹2.2B	₹2.4B	₹2.2B
Operating Income (EBIT)	₹797M	₹778M	₹371M	₹680M	₹594M
Net Income	₹502M	₹552M	₹405M	₹453M	₹539M

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AARTIDRUGS Free Cash Flow History

Cash flow	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Dividends Paid	(₹182M)	(₹91M)	(₹93M)	(₹94M)	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AARTIDRUGS Balance Sheet History

Balance sheet	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Assets	₹28.2B	₹25.7B	₹24.3B	₹24.2B	—
Total Liabilities	₹12.7B	₹12.1B	₹11.5B	₹12.3B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive AARTIDRUGS viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

4554 · Fuji Pharma Co., Ltd. — JPY 49 billion
RPGLIFE · RPG Life Sciences Limited — ₹46 billion
2196 · Shanghai Fosun Pharmaceutical (Group) Co., Ltd. — HK$46 billion
GUFICBIO · Gufic Biosciences Limited — ₹44 billion
UNICHEMLAB · Unichem Laboratories Limited — ₹38 billion
4577 · Daito Pharmaceutical Co.,Ltd. — JPY 38 billion
GALD · Galderma Group AG — CHF 37 billion
SOLARA · Solara Active Pharma Sciences Limited — ₹36 billion

← AARTECH All “A” companies AARTIIND →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.